EPS for Seres Therapeutics, Inc. (MCRB) Expected At $-0.73

February 20, 2018 - By Hazel Jackson

 EPS for Seres Therapeutics, Inc. (MCRB) Expected At $ 0.73

Analysts expect Seres Therapeutics, Inc. (NASDAQ:MCRB) to report $-0.73 EPS on March, 15.They anticipate $0.10 EPS change or 15.87 % from last quarter’s $-0.63 EPS. After having $-0.17 EPS previously, Seres Therapeutics, Inc.’s analysts see 329.41 % EPS growth. The stock increased 1.95% or $0.18 during the last trading session, reaching $9.42. About 101,361 shares traded. Seres Therapeutics, Inc. (NASDAQ:MCRB) has declined 64.58% since February 20, 2017 and is downtrending. It has underperformed by 81.28% the S&P500.

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Coverage

Among 9 analysts covering Seres Therapeutics Inc (NASDAQ:MCRB), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Seres Therapeutics Inc had 23 analyst reports since July 21, 2015 according to SRatingsIntel. As per Tuesday, July 21, the company rating was initiated by Goldman Sachs. The firm has “Buy” rating by Oppenheimer given on Thursday, October 12. Canaccord Genuity initiated Seres Therapeutics, Inc. (NASDAQ:MCRB) on Wednesday, July 22 with “Buy” rating. On Friday, July 29 the stock rating was initiated by H.C. Wainwright with “Buy”. On Thursday, October 22 the stock rating was upgraded by Bank of America to “Buy”. H.C. Wainwright initiated Seres Therapeutics, Inc. (NASDAQ:MCRB) rating on Monday, January 25. H.C. Wainwright has “Buy” rating and $55 target. The company was maintained on Monday, June 12 by Canaccord Genuity. The company was maintained on Friday, August 12 by FBR Capital. The stock of Seres Therapeutics, Inc. (NASDAQ:MCRB) has “Buy” rating given on Thursday, October 19 by Cantor Fitzgerald. The rating was initiated by Leerink Swann on Tuesday, July 21 with “Outperform”.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company has market cap of $381.79 million. The Company’s lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection . It currently has negative earnings. The firm also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI.

More notable recent Seres Therapeutics, Inc. (NASDAQ:MCRB) news were published by: Fool.com which released: “Why Seres Therapeutics Inc. Stock Is Tanking Today” on October 02, 2017, also Businesswire.com with their article: “Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in …” published on December 04, 2017, Businesswire.com published: “Seres Therapeutics to Present at the 36th Annual JP Morgan Healthcare Conference” on January 04, 2018. More interesting news about Seres Therapeutics, Inc. (NASDAQ:MCRB) were released by: Fool.com and their article: “Here’s What’s Lifting Seres Therapeutics Inc.’s Stock Price Today” published on March 16, 2017 as well as Businesswire.com‘s news article titled: “Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for …” with publication date: November 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.